C4 Therapeutics

C4 Therapeutics

C4 Therapeutics was founded in 2015 by a scientific team including James Bradner, then of Dana-Farber Cancer Institute, Kenneth Anderson, and Nathanael Gray, with Bradner's lab having pioneered the foundational chemistry for targeted protein degradation. The company raised its initial $73 million Series A from a syndicate that included Cobro Ventures, Roche, and Novartis. Bradner later joined Novartis as president of the Institutes for BioMedical Research, deepening the strategic tie between the two organizations. The firm went public via a Nasdaq IPO in October 2020, raising approximately $182 million. The company is built around the TORPEDO platform, which designs bifunctional degrader molecules known as PROTACs and molecular glues. These agents co-opt the E3 ubiquitin ligase machinery to tag oncogenic and other disease-causing proteins for proteasomal degradation, a mechanism that allows them to target proteins previously considered 'undruggable' by small-molecule inhibitors. Pipeline candidates span heme-oncology, solid tumors, and inflammatory diseases. CFT7455, the lead clinical asset targeting IKZF1/3, entered human trials in 2021 under an IND cleared by the FDA. A strategic collaboration with Biogen, signed in 2018 and expanded in 2020, focuses on neurological degrader targets. The partnership with Roche, which began at formation, continued with a broader interest in the platform. C4 retains full rights to its oncology pipeline while sharing certain neurology programs. As of its last public disclosures, C4 Therapeutics employed over 100 professionals at its Watertown, Massachusetts headquarters. The company remains majority-controlled by its public shareholders, with no single parent entity. Foundational investors and strategic partners, including Novartis and Biogen, have representatives on the scientific advisory board. C4 has not disclosed a dedicated philanthropic arm, but its scientific founders continue to hold academic appointments at Dana-Farber and Stanford, maintaining the translational-research pipeline that feeds the company. C4's structural advantage rests on the patent estate around the TORPEDO platform and the deep integration with the Bradner lab's original chemistry. Unlike conventional biotechs pursuing a single target, the degrader mechanism is a generalizable modality — if one protein can be tagged for destruction, the library can be screened against the entire proteome. This platform logic attracted the early strategic investments from Roche and Novartis, placing C4 at the center of a competitive landscape that includes Arvinas and Nurix Therapeutics, while benefiting from a first-mover position in the clinic for specific IKZF1/3 degraders.